CSPC Pharmaceutical Group (XTER:CVG) Debt-to-Equity: N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:CVG CSPC Pharmaceutical Group Ltd XTER:CVG
84 GF Score
Price €0.40
GF Value €0.29
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Debt-to-Equity?

CSPC Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0 Mil. CSPC Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0 Mil. CSPC Pharmaceutical Group's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CSPC Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:

XTER:CVG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.02   Max: 0.18
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of CSPC Pharmaceutical Group was 0.18. The lowest was 0.00. And the median was 0.02.

XTER:CVG's Debt-to-Equity is ranked better than
92.84% of 810 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs XTER:CVG: 0.02

CSPC Pharmaceutical Group  (XTER:CVG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CSPC Pharmaceutical Group Debt-to-Equity Related Terms

CSPC Pharmaceutical Group Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Debt-to-Equity Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 0.02 0.02 0.02

CSPC Pharmaceutical Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 N/A 0.02 N/A 0.02

XTER:CVG vs LLY, JNJ, ABBV: Debt-to-Equity Comparison

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Debt-to-Equity falls into.


XTER:CVG
84GF Score
CSPC Pharmaceutical Group Ltd XTER:CVG
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CSPC Pharmaceutical Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(55.826 + 21.909) / 4022.909
=0.02

CSPC Pharmaceutical Group's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is CSPC Pharmaceutical Group (XTER:CVG) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of €0.40 is trading 37.9% above its estimated GF Value™ of €0.29.

Key valuation signals for XTER:CVG:

  • Debt-to-Equity: N/A
  • GF Value™: €0.29 vs. price of €0.40 (37.9% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the XTER:CVG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
84GF Score

Get the complete analysis for XTER:CVG

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price
€0.29
GF Value